# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹965 Cr** total (+23.3% YoY, +9.8% QoQ) · **₹961 Cr** consolidated operations (+23.6% YoY, +10.2% QoQ) * EBITDA: ₹208 Cr (–6.7% YoY, +4.3% QoQ) · 21.6% margin (–690 bps YoY, –110 bps QoQ) * **PAT:** **₹72 Cr** (–41% YoY, –15% QoQ) · **EPS:** **₹1.67** (–37.7% YoY, –14.7% QoQ) * **Cash & Equivalents:** **₹120 Cr** as of Sep 30, 2025 ## B. Revenue Growth * **Resilient Top-Line Performance:** Revenue growth outpaced seasonal headwinds, supported by strong execution in core markets and early benefits from operational ramp-up. * **CGHS Price Impact Ahead:** Upcoming **15–20% price increase** in select clusters (representing **~5–6% of total revenue**) expected to boost future margins and earnings contribution. ## C. EBITDA & Margins * **Margin Pressure Amid Expansion:** EBITDA margin contraction YoY despite QoQ improvement, driven by dilutive impact from new hospitals not yet at breakeven. * **Core Asset Strength Persists:** **Telangana and Andhra clusters** sustain **25–30% EBITDA margins**, with Andhra margin rising to **nearly 28%** on strong Srikakulam ramp-up and Quens NRI turning EBITDA positive. * **CGHS Contribution Outlook:** Incremental revenue from price revision expected to flow through to EBITDA at **~60% incremental margin**, adding **₹10–12 Cr annual EBITDA** run-rate next fiscal. ## D. Profitability Trends * **Earnings Under Pressure:** PAT declined significantly YoY and QoQ, reflecting margin compression and higher pre-operating costs from expansion pipeline. ## E. Cash Position * **Healthy Liquidity Buffer:** Strong cash position maintained at **₹120 Cr**, providing flexibility for ongoing capital deployment without immediate funding needs. --- # 2. Occupancy & Volume Trends ## A. Key Figures * Inpatient Volume: 64,288 (+12.2% QoQ, +15.3% YoY) * **Outpatient Volume:** **592,725** (+18% QoQ, +1% YoY) * ARPOB: Growth of 9.8% YoY, -2.3% QoQ ## B. Volume & Capacity Dynamics * **Resilient Volume Growth:** Inpatient and outpatient volumes show sustained momentum despite lower occupied beds in Andhra, driven by reduced ALOS and capacity expansion. * **Operational Transitions Impacting Utilization:** Telangana cluster occupancy remains around 50% due to **300 beds under rehabilitation in Secunderabad**, while Thane hospital operates at **80–90 beds** as of October. * **No Actual Bed Reduction in Maharashtra:** Reported changes in census/non-census beds were due to a **data typo**; total bed count remains unchanged Q1 to Q2. ## C. Revenue & Margin Outlook * **ARPOB Expansion Trajectory:** Consolidated ARPOB on path to reach **₹50,000 over 8 quarters**, led by performance potential in Thane and Bangalore (**₹65,000–70,000**), mirroring Hyderabad levels. * **Strong Regional Profitability:** Andhra region delivers **double-digit revenue growth** on the back of rising ARPOBs and is expected to sustain a **28% EBITDA margin**. * **New Hospital Ramp-Up Strategy:** Initial ARPOB at new facilities will be **lower due to limited insurance empanelment and strategic pricing**, but expected to improve with maturing case mix and pricing power. * **Proven High-Margin Model:** Existing **220-bed Kondapur hospital generates ₹350 Cr revenue** with **over 30% profit margin**, validating scalability of the large-format model. * **Margin Target Intact:** Despite incremental opex from launching **oncology and transplant services**, company remains committed to maintaining a **high 20% EBITDA margin**. --- # 3. Hospital Ramp-Up & Capacity ## A. Key Figures * **Surgeries Performed:** **>1,000** at Thane centre in <6 months * **Bed Additions (Past Year):** **~3,000–4,000** new beds * **Kondapur Bed Expansion:** **+550 beds** (total ~770) * **Srikakulam Bed Addition:** **+150 beds** * **Recent Quarterly Additions:** **+100 beds** in Andhra (Srikakulam), **+65 beds** in Telangana (Begumpet) ## B. New Facility Progress * **Strong Ramp-Up Momentum:** New facilities in Thane and Mahadevapura showing accelerated performance, with high patient uptake and early clinical milestones achieved. * **Favorable Market Entry Dynamics:** Expansion in Bengaluru targeting underserved micro-markets with lower competitive intensity, supported by secured clinical talent despite presence of major players. * **Upcoming Commissioning:** PES and one Bangalore facility set to launch imminently; Secunderabad rehab and Kondapur expansion expected by Q1 next FY, boosting Telangana cluster growth. ## C. Bed Expansion * **Scaled Capacity Buildout:** Significant near-term bed addition program completed across clusters, with only Kondapur pending—set for commissioning within 6 months. * **Long-Term Scalability:** Secunderabad unit has potential for **+150–200 beds** (total ~1,200), though rollout expected over 5 years. ## D. Operational Bed Utilization * **Phased Ramp-Up Strategy:** Initial activation of 100–150 beds in Thane despite full infrastructure; expansion tied to **70–80% occupancy thresholds**, minimizing incremental capex. * **Utilization Gap to Narrow:** Full bed capacity expected to come online progressively as demand grows, with infrastructure already in place. --- # 4. Payer & Revenue Mix ## A. Key Figures * **CGHS Revenue Contribution:** **~10%** of total revenue · **35–40%** in Nashik cluster * **Nashik Payer Mix:** **70%** credit (insurance + CGHS) · **30%** cash * CGHS Price Hike Impact: 15–20% price increase in AP/Telangana/Nagpur clusters, contributing ~10% to revenue in these regions * **Tier 2 City Payer Profile:** **25%** CGHS-related · **20–40%** insurance · remainder cash ## B. Insurance Empanelment * **Progress Toward Full Coverage:** Empanelment with all top five insurers advancing across Thane, Nashik, and Bengaluru, with completion expected by **Q4**. * **Nashik Leading Execution:** 2 of top 5 insurers already empaneled; remaining 3 on track for year-end closure. * **Market-Specific Negotiations:** Pricing discussions emphasize value from new infrastructure, with no current trade-offs between core and new markets. ## C. CGHS & Corporate Payers * **High-Volume, High-Impact:** CGHS patients—classified under corporate payers—drive outsized revenue in AP and Telangana, where the company holds the largest patient share. * **Leveraging Regulatory Milestones:** Post-CGHS license, pursuit of ECHS, ESI, and other empanelments will unlock significant revenue potential. * **Clustered Revenue Sensitivity:** Nashik’s dependence on CGHS (35–40%) makes empanelment urgency higher than in Thane or Bangalore. ## D. Regional Payer Profile * **Affordability as Growth Lever:** Deliberate pricing below peers (e.g., Manipal, Narayana, Jupiter) in new markets to accelerate patient acquisition and market penetration. * **Consistent Tier 2 Blueprint:** Payer mix in new locations (Thane, Bangalore, Kerala) is being modeled after successful AP/Telangana/Nagpur frameworks. --- # 5. Specialty & Service Expansion ## A. Key Figures * **Revenue Mix:** **17%** from cardiac sciences · **14%** from orthopedics · **11%** from neurosciences * **Growth Outlook:** Andhra region supports **mid- to high-teens revenue growth** potential ## B. Clinical Program Launches * **Strategic Specialty Expansion:** Launched comprehensive cardiac unit in Nashik—**only center in North Maharashtra** offering both EP studies and ECMO—bolstering regional leadership. * **Transplant Program Momentum:** Rapid advancement in transplant capabilities with **first multi-organ transplants** at both Guntur and Mahadevapura units within early operational phases. * **Holistic Care Model:** Expanding beyond curative services into **preventive care, post-discharge rehabilitation, and palliative oncology support**, aligning with evolving patient needs. ## C. Technology Investments * **Pioneering Digital Surgery:** Deployed **Telangana and Andhra Pradesh’s first Medtronic robotic guidance system** for spine surgery at Kondapur, enhancing precision and outcomes. * **XR & AI Innovation:** Launched **Asia’s first XR Experience Lab** at Gachibowli, demonstrating **measurable improvements in patient experience** during pilot, including reduced anxiety and analgesia use. * **Sustained Tech Commitment:** Expanded surgical robotics footprint with **25 DaVinci systems** and introduced **Gamma Knife, TULSA-PRO, and MR-guided FUS**, reinforcing tech-driven care differentiation. ## D. Academic & Medical Recognition * **Global Clinical Excellence:** KIMS team secured **India’s first gold medal** in the **40+ year history of the ACR Knowledge Bowl**, defeating elite global institutions, and earned the Team Spirit Award. * **Individual Leadership Recognition:** **Dr. Manas Panigrahi** delivered keynote at **Congress of Neurological Surgeons (LA)**; **Dr. Aswini Dutt** honored as **Best Nephrologist in Hyderabad** with Dr. APJ Abdul Kalam Award. * **Rapid Clinical Impact:** KIMS Kannur achieved **32 first-in-kind procedures in first 32 weeks**, underscoring accelerated clinical adoption and innovation. --- # 6. Risks & Ramp-Up Challenges ## A. Key Figures * **EBITDA Loss per New Hospital:** **INR20–30 Cr** during 12-month ramp-up * **Fixed Cost (Thane Cluster):** **INR12–15 Cr/month** * **PES Hospital Loss Contribution:** **30% of INR25 Cr** Bengaluru EBITDA loss ## B. New Hospital Ramp-Up Dynamics * **Ramp-Up Phase Impact:** Financial drag from **4–5 newly commissioned large-format hospitals** in Maharashtra, Kerala, and Karnataka, most launched within the last 10 months and typically requiring ~1 year to breakeven. * **Positive Early Trends:** Thane hospital shows encouraging ramp-up despite being operational for only **45 days in Q1**; similar trajectory expected across new clusters. * **Doctor Onboarding Hurdle:** Delays persist due to medical staff reluctance to join before insurance and CGHS empanelments are secured, affecting initial patient inflow. ## C. Regulatory & Empanelment Progress * **CGHS Licensing Accelerating:** Nashik hospitals await 17(2)(ii)b license—historically 9–12 months, but now expected within **next 2 months**, easing a key bottleneck. * **Insurance Empanelment Improving:** Delays are resolving as regulatory clarity emerges on GIC guidelines, supporting faster revenue ramp-up. * **No Cannibalization Risk:** Kondapur and Gachibowli hospitals, though **4 km apart**, serve distinct catchments, preserving market expansion integrity. ## D. Operational Model & Confidence * **O&M Accounting Neutrality:** Sangli and Guntur operate under revenue share agreements, making EBITDA performance **invisible in company accounts**, despite Sangli delivering strong operational results. * **Management Confidence:** Leadership affirms all new hospitals are executing **exactly as planned**, with no operational deviations. --- # 7. Guidance & Outlook ## A. Key Figures * **Breakeven Revenue (Thane):** **₹15 Cr** (incl. consumables) · **Fixed Cost:** **₹5 Cr** * **Consolidated EBITDA Margin Guidance:** **27–30%** (2–3 year outlook) · **Near-term:** early **20s%** (next two quarters) * **Sustainable Margin (Andhra):** **25–28%** * **Revenue Potential (Kondapur):** **₹1,000 Cr** future facility ## B. Breakeven Timeline * **Guidance Confirmed:** All new facilities expected to reach cost neutrality within **12 months of commissioning**, with group-wide EBITDA breakeven targeted by **June next year**, excluding one uncommissioned Bangalore unit. * **Thane Progress:** Hospital on track to breakeven in **next 2 months**, supported by strong ramp-up across **~130 operational beds** and recent revenue momentum. * **Correction Clarified:** Mahadevpura (Bangalore) breakeven timeline corrected to **12 months post-commissioning**, not 2 months, following presentation typo. * **Path to Profitability:** Majority of current losses stem from new units; management expects all **24–25 operational facilities to reach breakeven by Q1**. ## C. Margin Recovery * **Near-term Pressure, Long-term Expansion:** Margins to remain in early **20s%** for two quarters due to new hospital ramp-up, but **expansion expected from Q1 onward** as units turn EBITDA positive. * **Profitability Trajectory:** **Significant improvement in overall profitability** anticipated by **FY '27 and beyond**, as newer hospitals mature toward corporate margin levels. * **Offsetting Factors:** **CGHS price increase** to partially mitigate margin pressure from launch-phase losses. * **Cluster-Specific Outlook:** Andhra cluster on track for **sustainable 25–28% margins**; Maharashtra cluster to see narrowing losses in Q3 despite flat bed count. ## D. Revenue Projections * **H2 EBITDA Loss Uncertainty:** No precise H2 EBITDA loss guidance due to dependency on stabilization of **Mahadevpura and PES hospitals** over the next two quarters. * **Long-term Scaling Potential:** Expanded Kondapur facility flagged as a future **₹1,000 Cr revenue contributor**, highlighting embedded growth optionality.